Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly’s tirzepatide in a head to head Phase 3 trial.
The readout from this pivotal study challenges Novo Nordisk’s efforts to strengthen its position in the competitive market for injectable weight loss therapies.
The result introduces fresh questions around CagriSema’s commercial potential and the company’s roadmap for future obesity treatments.
Novo Nordisk, known for its diabetes and obesity treatments, has been a central player in the fast growing market for weight loss drugs. The CagriSema outcome arrives as investor, prescriber, and patient interest in obesity therapies remains high, and as large pharmaceutical peers increase their focus on this area. For holders of CPSE:NOVO B, the trial result is a recent data point on how competition in obesity care is developing.
For investors, the key questions now center on how Novo Nordisk positions CagriSema alongside its existing obesity portfolio and how it responds to Eli Lilly’s tirzepatide data. Future company updates on regulatory plans, label ambitions, and any changes in research priorities are likely to be important markers for understanding Novo Nordisk’s direction in obesity treatments.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B Earnings & Revenue Growth as at Feb 2026
We’ve flagged 5 risks for Novo Nordisk. See which could impact your investment.
The CagriSema result puts Novo Nordisk under more pressure in injectable obesity drugs, especially against Eli Lilly’s tirzepatide, which now has a clearer efficacy edge in this head to head setting. For a company already dealing with pricing pressure, patent headwinds and rising competition from Lilly and other large pharma peers, this trial outcome may narrow Novo Nordisk’s room to rely on premium positioning for its next generation injectable. At the same time, CagriSema still produced meaningful weight loss and fits into Novo Nordisk’s broader cardiometabolic portfolio, which now spans injectable and oral GLP 1 treatments, including the recently approved Wegovy pill and higher dose Wegovy injection options in Europe. For investors, this raises the importance of how Novo Nordisk balances its injectable pipeline, potential higher dose CagriSema studies and possible business development against the growth potential in oral obesity treatments, where it already has a first approved product and where Eli Lilly and other players are also building positions.
The CagriSema data still support the long term theme in the narrative that global demand for GLP 1 obesity and diabetes therapies is large, reinforcing the relevance of Novo Nordisk’s broad pipeline and existing products.
The underperformance versus tirzepatide challenges the idea that next generation injectables alone can carry future growth, especially when the narrative highlights pricing pressure and competition as key risks.
The narrative places strong emphasis on oral obesity treatments as future growth drivers, and this trial result may increase the weight of that element more than originally assumed.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk to help decide what it is worth to you.
⚠️ The CagriSema result highlights competitive risk, with Eli Lilly currently setting a high efficacy bar in obesity injectables that could make it harder for Novo Nordisk to defend share and pricing.
⚠️ Analysts have already flagged risks from pricing pressure, generic competition and high capital spending, and a less competitive next generation injectable could magnify those headwinds if volumes or mix shift unfavorably.
🎁 Novo Nordisk still reports strong historical earnings growth and is assessed as trading at good value compared to peers, which may support the investment case for those who see the obesity and diabetes opportunity as multi decade.
🎁 A broad pipeline that includes oral GLP 1 obesity treatments and CagriSema in diabetes, plus continued R&D, gives multiple shots on goal rather than relying on a single product outcome.
From here, it is worth watching how regulators respond to the CagriSema filing, what Novo Nordisk discloses on the planned higher dose trials, and how physicians and payers frame the trade off between CagriSema and tirzepatide on efficacy, tolerability and convenience. Updates on oral Wegovy uptake, further label expansions for semaglutide, and any comments on pricing trends or generic pressure at results calls may also reshape expectations for Novo Nordisk’s obesity and diabetes revenue mix.
To ensure you are always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com